Fundz

Centauri Therapeutics receives an additional $5.1M grant from CARB-X to advance ABX-01 to clinical trials, bringing total support to $12.3M since 2019.

PRIVATEJul 29, 2025

Amount Raised

$5.1 Million

Round Type

Grant

LondonOtherBiotechnologyHealth CareTherapeutics

Investors

Carb X

Description

Centauri Therapeutics has announced that CARB-X has provided an additional $5.1M in funding for the development of their lead compound. This funding will aid in advancing their ABX-01 programme into first in human clinical studies. The grant marks CARB-X’s continued support, totaling $12.3M since 2019. The ABX-01 candidate targets serious Gram-negative bacterial infections.

Who to call at Centaurus Therapeutics, and when

A new round usually means Centaurus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Centaurus Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Centaurus Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Centaurus Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Centaurus Therapeutics

Location

London, England, United Kingdom

About

Centauri Therapeutics Limited is a UK-based biotechnology company developing novel treatments for life-threatening diseases using its proprietary Alphamer technology. This approach harnesses "programmable immunity" by redirecting natural antibodies to target pathogens, using molecules that bind to pathogens and present epitopes to trigger an immune response. Backed by strong IP and a portfolio of patents, Centauri is advancing specific leads with the potential to deliver fast, targeted antibacterial therapies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Centaurus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts2 people are listed at Centaurus Therapeutics. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Centaurus Therapeutics's next move

See what Strategic adds

Centaurus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.